Gilead Sciences stock (US3755581036): Biotech leader navigates HIV and oncology markets

Gilead Sciences continues to drive innovation in HIV treatments and oncology, with Biktarvy maintaining strong market leadership amid evolving competitive pressures in virology.

Gilead Sciences, a leading biopharmaceutical company, reported steady performance in its core HIV franchise during the first quarter of 2025, according to its Q1 2025 earnings release as of April 24, 2025. Biktarvy sales reached $3.7 billion for the quarter, up 7% year-over-year, underscoring the drug's dominance in the US market where it holds over 50% share among treated patients.

The stock traded at $78.45 USD on May 10, 2026 on Nasdaq, according to Yahoo Finance as of 05/10/2026. This reflects a 1.2% gain over the prior week amid broader biotech sector recovery.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gilead Sciences, Inc.
• Sector/industry: Biopharmaceuticals / Virology and Oncology
• Headquarters/country: Foster City, California, USA
• Core markets: US, Europe, Asia-Pacific
• Key revenue drivers: HIV antivirals, oncology therapies
• Home exchange/listing venue: Nasdaq (GILD)
• Trading currency: USD

Gilead Sciences: core business model

Gilead Sciences focuses on developing therapies for life-threatening diseases, with a primary emphasis on virology, oncology, and inflammation. The company pioneered nucleotide analog technology for HIV treatment, starting with Viread in 2001. Today, its portfolio spans HIV, hepatitis, and cancer drugs, generating revenue primarily from patented antivirals.

Headquartered in Foster City, California, Gilead employs over 18,000 people worldwide. Its business model relies on R&D investment, averaging $4-5 billion annually, to extend blockbuster franchises and launch next-generation therapies, according to its 2024 Annual Report published February 2025.

Main revenue and product drivers for Gilead Sciences

HIV remains Gilead's cornerstone, accounting for 60% of 2024 revenue at $27.1 billion. Biktarvy, a single-tablet regimen, drove $14.6 billion in 2024 sales, up 10% from prior year, per the annual report. Trodelvy, its antibody-drug conjugate for metastatic breast cancer, posted $845 million in 2024, with Q1 2025 sales at $230 million, up 25% year-over-year.

Oncology contributes growing share, with recent approvals expanding Trodelvy's label. Veklury (remdesivir) for COVID-19 added $2.4 billion in 2024 but faces declining demand post-pandemic. Key drivers include label expansions and combination therapies in HIV to counter generic competition.

Industry trends and competitive position

The HIV market, valued at $28 billion globally in 2024 per IQVIA Global Medicine Use in 2024, sees Gilead holding 40% US share. Competitors like GSK's Dovato challenge with two-drug regimens, but Biktarvy's efficacy retains prescribers. In oncology, Trodelvy competes with Enhertu (Daiichi Sankyo/AstraZeneca), targeting similar TNBC patients.

Biotech trends favor precision medicine and ADCs, areas where Gilead invests via acquisitions like Immunomedics for $21 billion in 2020. US investors track Gilead for its defensive HIV cash flows amid volatile oncology pipelines.

Why Gilead Sciences matters for US investors

Gilead generates 70% of revenue from the US, per 2024 annual report, tying it closely to American healthcare spending and payer dynamics. Nasdaq-listed (GILD), it offers dividend yield around 3%, appealing to income-focused portfolios. Exposure to Medicare Part D and IRA drug pricing reforms directly impacts profitability.

Conclusion

Gilead Sciences maintains leadership in HIV therapeutics while expanding oncology presence through Trodelvy and pipeline assets. Q1 2025 results highlight franchise resilience, though patent cliffs loom post-2030. US investors value its market position and dividend amid biotech uncertainties.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.